{"entity":{"id":"nct07356973","kind":"trial","name":"Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma","aka":[],"tldr":"A phase 2 trial of irinotecan-ChemoSeed implementation into the resection cavity after surgical resection of GBM in glioma & glioblastoma, run by CRISM Therapeutics LTD, now recruiting.","summary":"Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma is a phase 2 interventional study registered as NCT07356973 by CRISM Therapeutics LTD, with 147 participants planned, started 2026-08-20 and due to reach its primary completion in 2029-05. Interventions recorded: irinotecan-ChemoSeed implementation into the resection cavity after surgical resection of GBM.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07356973","url":"https://clinicaltrials.gov/study/NCT07356973"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07356973","phase":"2","setting":"Open-label Phase 2 Safety and Efficacy Trial of Irinotecan-ChemoSeed Administered Directly Into the Resection Margin in Patients With Surgically Resectable Glioblastoma","sponsor":"CRISM Therapeutics LTD","enrolled":147,"outcomes":[]},"route":"/trials/nct07356973/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}]}}